Lum, L. G., Hari, P., Szabo, A., Donato, M., Park, J. H., Fowler, D. H., . . . Felizardo, T. C. Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. BMJ Publishing Group.
Chicago Style (17th ed.) CitationLum, Lawrence G., et al. Rapamycin-resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory Multiple Myeloma. BMJ Publishing Group.
MLA (9th ed.) CitationLum, Lawrence G., et al. Rapamycin-resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory Multiple Myeloma. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.